Skip to content
Catalyst

PapersPMID:41285561

Intermittent hypoxia and caffeine in infants born preterm: the ICAF Randomized Clinical Trial.

Archives of disease in childhood2026The record ↗

  1. Finding, moderate evidencelowersTumour necrosis factor alpha concentration

What moved

1 findingHow to read these marks →
  • “TNF-α at 38 weeks was 23% lower in the caffeine group compared to placebo, adjusting for baseline and covariates (P < 0.02, Table 3).”
    Study
    RCT
    Dose studied
    caffeine base 5 mg/kg/day once daily, escalating to 5 mg/kg twice daily at 36 weeks PMA, continued through 42 weeks 6 days PMA
    Population
    very preterm infants (<=30 weeks + 6 days gestational age) randomised to extended caffeine therapy through 42 weeks 6 days PMA vs placebo; secondary endpoint

Study record

Design
randomised controlled trial
Species
human
Population
preterm infants <30 weeks+6 days gestational age at 16 US hospitals, previously on routine caffeine, randomised after discontinuation to extended caffeine therapy or placebo through 42 weeks+6 days postmenstrual age
Participants
160
Comparator
not stated in the paper
Duration
not reported
Endpoints measured
9